News

Pipeline – 8/1/22

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

WALTHAM, Mass., and DUBLIN – October 27, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 […]

Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition

–Jodie Morrison appointed as Board Member and Acting CEO– Waltham, Mass. – September 20, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson. “Jodie has a deep background in executive, operational and […]

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive […]

Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition Waltham, Mass. – June 23, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data demonstrating the therapeutic potential of […]

Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia “Resolution of Inflammation” Conference

Dr. Violette also organizing the “Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies” conference at the Keystone Symposia Waltham, Mass. – June 8, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present “Targeting Complement in […]